40425_2019_723_MOESM2_ESM.jpg (123.91 kB)
Additional file 2: of Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
figure
posted on 2019-10-22, 19:05 authored by Arun Rajan, Christopher Heery, Anish Thomas, Andrew Mammen, Susan Perry, Geraldine OâSullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi Madan, Leomar Ballester, Stefania Pittaluga, Renee Donahue, Yo-Ting Tsai, Lauren Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen Hewitt, Jeffrey Schlom, Raffit Hassan, James GulleyFigure S1. PD-L1 expression in thymoma and thymic carcinoma. (A, E) WHO B3 thymoma with 95% thymic epithelial cell PD-L1 positivity and 3+ intensity. (B, F) WHO B2 thymoma with 50% thymic epithelial cell PD-L1 positivity and 2+ intensity. (C, G) Thymic carcinoma with 90% thymic epithelial cell PD-L1 positivity and 2+ intensity. (D, H) Thymic neuroendocrine carcinoma with focal thymic epithelial cell PD-L1 positivity and 1+ intensity. (A-D: 10x magnification; E-H: 40x magnification.). (JPG 123 kb)
